| Description | LY 186126 is a potent cGI-PDE inhibitor with reversible, high affinity (Ka = 6 nM) binding to a single class of SaR binding sites. |
| Synonyms | LY-186126, LY186126 |
| molecular weight | 285.34 |
| Molecular formula | C16H19N3O2 |
| CAS | 100644-00-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Ashikaga T, Robertson DW, Sportsman RJ, Strada SJ, Thompson WJ. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):315-37. PubMed PMID: 8968964. 2. Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther. 1993 Jun;265(3):1142-51. PubMed PMID: 8389853. 3. Flawn P, Loten EG. Properties and distribution of cyclic AMP phosphodiesterase from rat liver. Int J Biochem. 1990;22(9):983-8. PubMed PMID: 1704319. 4. Artman M, Robertson DW, Mahony L, Thompson WJ. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium. Mol Pharmacol. 1989 Aug;36(2):302-11. PubMed PMID: 2505059. |